{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:19:30Z","timestamp":1787015970813,"version":"build-2736575974"},"reference-count":102,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) disease impacts morbidity and mortality in hematopoietic cell transplant (HCT) recipients. This systematic review summarized data on the epidemiology, management, and burden of CMV post\u2010HCT outside of Europe and North America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The MEDLINE, Embase, and Cochrane databases were searched for observational studies and treatment guidelines in HCT recipients across 15 selected countries from Asia\u2010Pacific, Latin America, and Middle East (search period: 1 January 2011\u201317 September 2021). Outcomes included incidence of CMV infection\/disease, recurrence, risk factors, CMV\u2010related mortality, treatments, refractory, resistant CMV, and burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2708 references identified, 68 were eligible (67 studies and one guideline; 45\/67 studies specific to adult allogeneic HCT recipients). The rates of CMV infection and disease within 1 year of allogeneic HCT were 24.9%\u201361.2% (23 studies) and 2.9%\u201315.7% (10 studies), respectively. Recurrence occurred in 19.8%\u201337.9% of cases (11 studies). Up to 10% of HCT recipients died of CMV\u2010related causes. In all countries, first\u2010line treatment for CMV infection\/disease involved intravenous ganciclovir or valganciclovir. Conventional treatments were associated with serious adverse events such as myelosuppression (10.0%) or neutropenia only (30.0%, 39.8%) and nephrotoxicity (11.0%) (three studies), frequently leading to treatment discontinuation (up to 13.6%). Refractory CMV was reported in 2.9%, 13.0%, and 28.9% of treated patients (three studies) with resistant CMV diagnosed in 0%\u201310% of recipients (five studies). Patient\u2010reported outcomes and economic data were scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The incidence of CMV infection and disease post\u2010HCT is high outside of North America and Europe. CMV resistance and toxicity highlight a major unmet need with current conventional treatments.\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid14083-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tid.14083","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T03:08:49Z","timestamp":1686193729000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: A systematic review"],"prefix":"10.1111","volume":"25","author":[{"given":"Sung\u2010Yeon","family":"Cho","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Department of Internal Medicine Seoul St. Mary's Hospital Catholic Hematology Hospital Vaccine Bio Research Institute College of Medicine The Catholic University of Korea  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[{"name":"Department of Haematology Istanbul University\u2010Cerrahpasa Cerrahpassa Medical Faculty  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-0249","authenticated-orcid":false,"given":"Clarisse M.","family":"Machado","sequence":"additional","affiliation":[{"name":"Virology Laboratory Institute of Tropical Medicine Faculty of Medicine University of S\u00e3o Paulo (LIM52\u2010FMUSP)  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderjeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Takeda Biopharmaceuticals India Pvt. Ltd.  Gurugram Haryana India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anudeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG\u2014Singapore Branch  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Demuth","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG\u2014Singapore Branch  Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Slavin","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Service Royal Melbourne Hospital  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v5.i4.287"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2016.031"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.17925\/EOH.2009.03.1.41"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201011\u2010679639"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.DMIH2\u20100022\u20102015"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432\u20102277.2005.00218.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112666"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010199410040\u201000002"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00043\u201019"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.491"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_14_1","unstructured":"World Health Organization.Global Index Medicus. World Health Organization. 2021. Retrieved July 5 2021.https:\/\/www.globalindexmedicus.net\/"},{"key":"e_1_2_11_15_1","volume-title":"Critical Appraisal Tools","author":"Johanna Briggs Institute"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.010"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010126705"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.62621"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2018.10.004"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010020\u201004156\u20106"},{"key":"e_1_2_11_21_1","first-page":"1951","article-title":"Strategy for cytomegalovirus reactivation prevention with ganciclovir and high dose of valacyclovir in allogeneic stem cell transplantation (Abstract 4076)","author":"Lopez M","year":"2020","journal-title":"ECCMID Abstract Book"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288\u2010018\u20100960\u2010y"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2017.05.007"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.635"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000986"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.04.033"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000397"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.06.009"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009\u20102137.2013.01.033"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.025"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13633"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2015.079"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.008"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010014\u20102190\u20101"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.2947"},{"key":"e_1_2_11_36_1","unstructured":"HuangH LiaoX LiC et\u00a0al.The incidence of CMV reactivation and CMV diseases in the haplo\u2010identical hematopoietic stem cell transplantation\u2014a single center experience (Abstract 8763). In:23rd Annual Congress of 2018 APBMT.2018."},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13096"},{"key":"e_1_2_11_38_1","first-page":"145","article-title":"Cytomegalovirus infection in autologous hematopoietic stem cell transplant patients with hematological diseases: a single center (Poster 547)","author":"Eren D","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010013\u20100049\u20109"},{"key":"e_1_2_11_40_1","first-page":"520","article-title":"The clinical features of cytomegalovirus infection and its effect on hematopoietic stem cell transplantation and effectiveness of antiviral treatment protocols (Poster 499)","volume":"53","author":"Akyol E","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010020\u201004201\u20104"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.13966"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009\u20102137.2014.05.036"},{"issue":"40","key":"e_1_2_11_44_1","first-page":"3135","article-title":"Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co\u2010activation of cytomegalovirus and Epstein\u2013Barr virus","volume":"94","author":"Song T","year":"2014","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0254\u20101785.2013.02.006"},{"issue":"4","key":"e_1_2_11_46_1","first-page":"971","article-title":"Clinical analysis of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Guo Z","year":"2012","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmz030"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.12.003"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756\u20108722\u20105\u201046"},{"issue":"6","key":"e_1_2_11_50_1","first-page":"331","article-title":"Clinical study on foscarnet prophylaxis and pre\u2010emptive therapy for cytomegalovirus infection in hematopoietic stem cell transplantation","volume":"26","author":"Yamei WU","year":"2017","journal-title":"J Leuk Lymph."},{"key":"e_1_2_11_51_1","first-page":"145","article-title":"Cytomegalovirus infection in allogeneic hematopoietic stem cell transplant patients with hematological diseases: a single center (Poster 546)","author":"Eren D","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246191"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2012.53.2.393"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.4274\/Tjh.2013.0244"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmm.IJMM_17_269"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13458"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2020.04.005"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2013.0238"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009\u20102137.2016.04.034"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620721998124"},{"key":"e_1_2_11_61_1","first-page":"173","article-title":"Clinical course and outcomes of patients with CMV infection post allogeneic stem cell transplant (Poster 744)","author":"Krishnamoorthi N","year":"2020","journal-title":"Blood Cell Therapy"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2016.0225"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009\u20102137.2021.03.046"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.109"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2015.07.011"},{"key":"e_1_2_11_66_1","first-page":"103","article-title":"CMV reactivation after haploidentical stem cell transplant posttransplant cyclophosphamide children (Oral 633)","author":"Kapoor R","year":"2020","journal-title":"Blood Cell Therapy"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009\u20102137.2016.02.046"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.10.037"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks043"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014172"},{"key":"e_1_2_11_71_1","first-page":"426","article-title":"Cytomegalovirus infection among pediatric patients undergoing hematopoietic stem cell transplant in an endemic area\u2014report from a tertiary care center in Saudi Arabia (Poster 438)","volume":"54","author":"Alsultan M","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"e_1_2_11_72_1","first-page":"456","article-title":"The role of combination prophylaxis in preventing cytomegalovirus (CMV) infection after ex vivo AB T\u2010cell\u2010depleted haploidentical hemaopoietic cell transplant (HHCT) in children (Poster 366)","volume":"55","author":"Han Kang S","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28742"},{"key":"e_1_2_11_74_1","first-page":"S206","article-title":"Clinic risk factors of refractory CMV reactivation following allogeneic aHSCT: a single\u2010center study in China","volume":"51","author":"Qiu H","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.189"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010128227"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw668"},{"key":"e_1_2_11_78_1","first-page":"263","article-title":"Epidemiology of resistant and refractory cytomegalovirus infection following solid organ or haematopoietic stem cell transplant: a systematic review","volume":"56","author":"Bergamasco A","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_79_1","unstructured":"CaliendoA.Overview of Diagnostic Tests for Cytomegalovirus Infection. UpToDate. 2016. Retrieved July 6 2022.https:\/\/www.medilib.ir\/uptodate\/show\/8291#top"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2016.04.005"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13206"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1261"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16147"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.11.012"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12961"},{"key":"e_1_2_11_86_1","first-page":"432","article-title":"Impact of CMV replication in overall survival in allogeneic HSCT recipients","volume":"54","author":"Sola Aparicio E","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.11.006"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.11.038"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.06.006"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy696"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000502"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.09.015"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13627"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009362"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2064992"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.03.019"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13054"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25574"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12877"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13994"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab298"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000956"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.14083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T13:34:12Z","timestamp":1700660052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.14083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/tid.14083"],"URL":"https:\/\/doi.org\/10.1111\/tid.14083","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"2023-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14083"}}